Key result
Mirtazapine use was suspected as the major associated factor in the development of venous thromboembolism in a woman with depression, though literature review yielded no definitive conclusion.
Why the study?
Does mirtazapine increase the risk of venous thromboembolism in patients with depression?
Case Report (n=1)
Does mirtazapine increase the risk of venous thromboembolism in patients with depression?
This case report and literature review suggests a possible but inconclusive association between mirtazapine use and venous thromboembolism.
Venous thromboembolism (VTE), including pulmonary thromboembolism (PTE) and deep venous thrombosis (DVT), is a common disease with a considerably high morbidity and mortality. Mirtazapine, a novel antidepressant with a unique mode of action, is currently widely used in psychiatric practice. Preliminary clinical studies have showed that it is an effective and fast-acting antidepressant with few side effects. Reports about mirtazapine inducing VTE are rare. We present a case of VTE in a woman with depression without any major risk factors for thrombosis where mirtazapine was suspected to be the major associated factor in the development of VTE. In addition, we reviewed the literature to further explore the association between antidepressant drug use and the risk of VTE. As a result, a possible association was indeed found between the two, but no conclusion could be drawn.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2011) conducted a case report in Depression and Venous Thromboembolism (n=1). Mirtazapine was evaluated on Venous thromboembolism. Mirtazapine use was suspected as the major associated factor in the development of venous thromboembolism in a woman with depression, though literature review yielded no definitive conclusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: